Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

“Patients with cancer don’t have time to wait for new treatments, so there is a strong need to compress the drug discovery ...

A trial drug has kept Desiree Dufour's breast cancer at bay — and now, the medication has been approved by the FDA. She has ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

With a federal grant in hand, researchers at the health system and national lab will try to hit fast forward on the long and ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

They will therefore further analyse drugs that target enzymes in other organs where enzyme activity levels vary. "We believe that by leveraging loss of heterozygosity and natural genetic variations in ...